With $110M to add to the bankroll, Generation Bio sets its sights on engineering a revolution in the gene therapy field

John Carroll

Editor & Founder

Whoever comes out on top of the current race to gain pioneering approvals for new AAV-delivered gene therapies will have to look over their shoulders …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With $110M to add to the bankroll, Generation Bio sets its sights on engineering a revolution in the gene therapy field

John Carroll

Editor & Founder

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Pharma's wins and losses in Trump's sprawling executive order on drug prices

US drugs rely heavily on ingredients made overseas, new report shows

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

With $110M to add to the bankroll, Gen­er­a­tion Bio sets its sights on en­gi­neer­ing a rev­o­lu­tion in the gene ther­a­py field

Editor & Founder

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

With $110M to add to the bankroll, Generation Bio sets its sights on engineering a revolution in the gene therapy field